Allianz Asset Management’s Structure Therapeutics GPCR Stock Holding History

Allianz Asset Management’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$408K	Sell	7,600 -1,000	-12%	-$44.2K	﹤0.01%	2014
2026 Q1	$415K	Sell	8,600 -3,400	-28%	-$233K	﹤0.01%	1861
2025 Q4	$835K	Buy	+12,000	New	+$490K	﹤0.01%	1747
2025 Q3	–	Sell	-11,000	Closed	-$228K	–	2027
2025 Q2	$228K	Buy	+11,000	New	+$242K	﹤0.01%	1936
2025 Q1	–	Sell	-8,800	Closed	-$239K	–	2267
2024 Q4	$239K	Hold	8,800	–	–	﹤0.01%	2068
2024 Q3	$386K	Sell	8,800 -3,000	-25%	-$116K	﹤0.01%	1921
2024 Q2	$463K	Buy	+11,800	New	+$485K	﹤0.01%	1861
2023 Q4	–	Sell	-5,500	Closed	-$277K	–	2176
2023 Q3	$277K	Buy	+5,500	New	+$177K	﹤0.01%	2079

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jupiter Topco New York $245B AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Allianz Asset Management's GPCR Position: Q2 2026 in Review

Allianz Asset Management reduced its Structure Therapeutics (GPCR) stake by 12% in Q2 2026, selling an estimated $44.2K and leaving 7,600 shares worth $408K. The position accounts for ﹤0.01% of the portfolio, ranked #2014.

Allianz Asset Management first reported a position in GPCR in Q3 2023 and has held it in 8 quarters since. The position peaked at $835K in Q4 2025. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

Allianz Asset Management held 7,600 shares of Structure Therapeutics worth $408K as of Q2 2026.
Allianz Asset Management sold 1,000 Structure Therapeutics shares in Q2 2026, an estimated $44.2K.
Structure Therapeutics made up ﹤0.01% of Allianz Asset Management's portfolio in Q2 2026, its #2014 holding.
Allianz Asset Management first reported a position in Structure Therapeutics in Q3 2023 and has held it in 8 quarters since.
Allianz Asset Management's Structure Therapeutics position peaked at $835K in Q4 2025.
191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Allianz Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.